TABLE III.
Summary patient demography and disease characteristics (n = 34 patients).
| Variable (units) | Number, median (range, %) |
|---|---|
| Age (yr) | 48 (31–67) |
| Body mass (kg) | 76 (45–105) |
| Height (m) | 1.65 (1.52–1.75) |
| Lean body mass (kg) | 48.7 (36.0–55.9) |
| Race | |
| African-American | 10 (29%) |
| Caucasian | 24 (71%) |
| Ethnicity | |
| Hispanic | 1 (3%) |
| Non-Hispanic | 33 (97%) |
| Affected breast | |
| Right only | 20 (59%) |
| Left only | 13 (38%) |
| Bilateral | 1 (3%) |
| TNM clinical stage | |
| Stage I | 1 (3%) |
| Stage IIA/IIB | 6 (18%)/7 (21%) |
| Stage IIIA/IIIB/IIIC | 12 (35%)/2 (6%)/1 (3%) |
| Stage IV (metastatic) | 2 (6%) |
| N/A | 3 (9%) |
| Tumor diameter | 5.0 cm (1.0–10.0 cm) |
| Clinical node status | |
| Positive | 19 (56%) |
| Negative | 9 (26%) |
| N/A | 6 (18%) |
| Tumor grade | |
| Low | 1 (3%) |
| Intermediate | 7 (21%) |
| High | 24 (71%) |
| N/A | 2 (6%) |
| Hormone receptor status | |
| ER (+/−/N/A) | 14 (41%)/19 (56%)/1 (3%) |
| PR (+/−/N/A) | 10 (29%)/23 (68%)/1 (3%) |
| HER2 (+/−/equivocal) | 13 (38%)/19 (56%)/1 (3%) |
| Triple negative (ER-, PR-, HER2-) | 11 (32%) |
Note: TNM = tumor-node-metastasis staging system; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; N/A = not available.